SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is experiencing an extraordinary surge, driven by a recent 13D filing indicating a single shareholder now owns a substantial portion of the company's shares. This has dramatically reduced the public float, leading to intense community speculation about a potential short squeeze and drawing comparisons to past high-volatility low-float runners. Traders are actively discussing the extreme scarcity of available shares, fueling significant momentum and robust buying interest in anticipation of continued upward movement.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is trending due to widespread community discussion focused on its ultra-low share float and significant short interest, sparking intense speculation about a potential short squeeze. Traders are actively drawing comparisons to past high-volatility stocks, with sentiment further fueled by a high cost to borrow and anticipation of upcoming earnings or contract news as potential catalysts for a substantial price movement. The community is closely monitoring for a breakout above key price levels.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing intense debate as it trades at multi-year lows despite broader market gains, with community sentiment sharply divided. While many express extreme frustration and criticize management for perceived underperformance, a contrarian view highlights strong fundamentals and potential for a significant rebound driven by anticipated midterm election spending and AI integration. The stock's future is a key talking point, especially as it navigates competitive pressures from major tech platforms and awaits upcoming earnings.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a key topic following its investor event, where the company significantly raised future revenue guidance and reported a substantially increased backlog, bolstered by a strong cash position. The community is actively debating its high valuation and the presentation quality, even as many anticipate continued long-term growth and potential for a short squeeze in its critical infrastructure and defense autonomous systems sectors. Discussion centers on whether the updated outlook justifies the current price and foreshadows further analyst upgrades.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending due to overwhelming positive clinical data, showing sustained complete responses in lymphoma patients, sparking significant community excitement about its potential in cancer treatment. This promising news, coupled with recent global approvals for Anktiva, is fueling a perceived short squeeze and massive trading volume as investors anticipate a major breakthrough in the biotech sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to a notable price decline, with community discussion frequently pointing to market manipulation and options-related 'max pain' as key drivers. This comes despite multiple analyst upgrades highlighting its AI-powered growth in mobile advertising and e-commerce, leaving investors questioning the immediate market dynamics amidst underlying bullish sentiment for the company's fundamentals.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a major talking point after a significant analyst upgrade to a Buy rating with a raised price target, intensifying community speculation about an upcoming AI deal. Discussion centers on the company's strategic advantage in power capacity for AI infrastructure, a critical bottleneck in the booming sector. While many anticipate substantial growth from its Neo-Cloud transition, some observers remain wary of valuation and potential market dynamics.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is experiencing notable upward momentum, fueled by prevailing strong demand within the AI infrastructure sector, echoed by bullish indicators from related industry leaders. This movement is intensifying amidst community discussions that largely dismiss a recent "sell" rating from a major financial institution, widely perceived as a strategy to accumulate shares at more favorable prices. Many investors consider SMCI a highly undervalued pure-play in the AI space, anticipating further positive re-evaluation as the company approaches its next financial disclosures.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending due to its pivotal multi-year data center leasing agreement with AMD, which includes a significant initial IT load capacity and options for substantial expansion at its Rockdale site. This deal is driving community excitement, seen as a strategic shift transforming Riot into a leading AI/HPC infrastructure provider with massive power capacity, potentially decoupling its valuation from Bitcoin and drawing comparisons to other major players.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing a significant surge following its selection for the U.S. Missile Defense Agency's SHIELD program, part of the broader Golden Dome defense strategy. This news is energizing a strong bullish community, who see it as validation of the company's dual-use satellite technology and a catalyst for a potential short squeeze, despite ongoing discussions regarding its valuation and revenue generation. Many long-term holders are celebrating what they view as a critical step in establishing ASTS as a national strategic asset in the rapidly evolving space sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.</li><li>The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.</li><li>The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;</li></ul>&nbsp;Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html">said</a>.<h2 class="st-heading-2">Path Forward</h2>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.<h2 class="st-heading-2">Executive Take Away</h2>According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.<blockquote>“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.” &nbsp; - Michael Myers, CEO, Quoin.</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNRX">QNRX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.QNRX stock is down by 59% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-talks-about-us-achilles-heel-when-it-comes-to-rare-earths/cLPdHr9REPH">Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Equity

Quoin Pharmaceuticals (QNRX) became the top-four trending ticker on Stocktwits on Friday morning after the stock jumped nearly 300% after the company announced that it has entered into a securities purchase agreement with new healthcare-focused institutional investors, with the potential to raise $104.5 million in gross proceeds.The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases said that this purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.The firm added that&nbsp;the private placement was priced at a premium to the company’s prior day’s closing stock price. Quoin said that the financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.Retail sentiment on <a href="https://stocktwits.com/symbol/QNRX">Quoin</a> jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Quoin said it will issue an aggregate of 1,993,940 American Depository Shares (ADSs) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants.The company said it intends to use the upfront net proceeds for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions, and general capital expenditures.&nbsp;The aggregate net proceeds are expected to be sufficient to fund the company into 2027. Shares of Quoin have gained nearly 41% this year and have jumped 76% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kalshi-doubles-valuation-to-5-b-in-latest-funding-round-report/ch6aClnR3SM">Kalshi Doubles Valuation To $5B In Latest Funding Round: Report</a>

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial clinical data from its ongoing investigational new drug Pediatric Peeling Skin Syndrome (PSS) study evaluating QRX003.Twelve weeks of treatment produced a clear improvement in the patient's skin condition compared to initial baseline measurements.&nbsp;The stock closed at $7.65 on Wednesday, rising 20.3% during the day, but slipped 8% to $7.04 in after-hours trading.Clinical endpoints such as The Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children's Dermatology Life Quality Index (CDLQI) showed positive changes.&nbsp;The patient's IGA score changed from severe to mild, M-IASI decreased from 36 to 12, and CDLQI, the quality of life measure, fell from 19 to 11. The study reported no adverse events while administering QRX003 to patients.Quoin will extend the patient's treatment while performing additional clinical evaluations after 24 weeks of therapy.&nbsp;The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition.Peeling Skin Syndrome is a rare genetic disorder that manifests through excessive outer skin shedding, leading to persistent pain and itching.&nbsp;Without any existing approved treatments, the promising results from QRX003 trials suggest its potential importance if future studies confirm the positive outcomes.CEO Michael Myers stressed the clinical importance of observed improvements and pointed out QRX003's potential to become the first approved therapy for PSS, noting plans to expand the study internationally.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,314% surge in 24-hour message volume.One user noted that some investors with less conviction tend to sell just before market close, expressing hope that the stock would open at $20.&nbsp;<stembedurl>https://stocktwits.com/89gt/message/614698425</stembedurl>Another user highlighted the stock’s potential for rapid movement due to its very low float and recent positive news.<stembedurl>https://stocktwits.com/MasterofThePennies/message/614637863</stembedurl>The stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Current Price	$10.50
Prev Close	$10.66
Open	$10.89
Dividend Yield	0.00%
50-Day Moving Average	$14.16
Beta	0.73
Avg. Volume	89,696.82
PE Ratio	-0.02

52-Week High	$41.80
52-Week Low	$5.01
Market Capitalization	$6.27M
EPS (Annual)	-$67.17
Price to Book	-5.16
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

QNRX
Quoin Pharmaceuticals Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest QNRX News

QNRXQuoin Pharmaceuticals Ltd - ADR